Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The P4v9 Trial: 4 Months Rifampin vs 9 Months Isoniazid for Latent TB in Children
NCT00170209Phase 3Completed
- Sponsor
- McGill University
- Start
- Aug 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of rifampicin in latent tuberculosis infection (LTBI) (2 arms), sponsored by McGill University. Primary endpoint: Adverse events of all grades. Started Aug 2011; status: completed.
02
Drugs
rifampicin
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT00170209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170209.